Results 21 to 30 of about 20,538 (302)

The opioid agonist morphine decreases the dyskinetic response to dopaminergic agents in parkinsonian monkeys

Neurobiology of Disease, 2004
In parkinsonian patients as well as in primate models with levodopa-induced dyskinesias (LID), an increase in the expression of preproenkephalin in the striatal output pathways has been demonstrated.
Pershia Samadi, Laurent Grégoire, Paul J Bédard   +2 more
doaj   +1 more source

Practical aspects of prescribing antiparkinsonian drugs. The place of amantadines in the management of Parkinson’s disease

Медицинский совет, 2021
Treatment of Parkinson’s disease (PD) includes the administration of dopaminergic and occasionally non-dopaminergic drugs, in mono- or in combination therapy.
N. V. Titova, A. A. Portupeev
doaj   +1 more source

Costs of Parkinson's Disease and Antiparkinsonian Pharmacotherapy: An Italian Cohort Study [PDF]

, 2010
Objective: Antiparkinsonian pharmacotherapy is costly and the determinants of drug costs in Parkinson's disease (PD) have been poorly investigated. The objective of this study was to investigate the costs of PD and antiparkinsonian drugs in an Italian ...
Balzer-Geldsetzer, Monika, Barone, Paolo, Bötzel, Kai, Campenhausen, Sonja von, Dodel, Richard, Eggert, Karla, Longo, Katia, Oertel, Wolfgang H., Reese, Jens P., Spiga, Giuseppe, Winter, Yaroslav   +10 more
core   +1 more source

Dopaminergic Treatment Effects on Dysarthric Speech: Acoustic Analysis in a Cohort of Patients With Advanced Parkinson's Disease

Frontiers in Neurology, 2021
Importance: The effects of dopaminergic treatment on speech in patients with Parkinson's disease (PD) are often mixed and unclear. The aim of this study was to better elucidate those discrepancies.Methods: Full retrospective data from advanced PD ...
Francesco Cavallieri, Francesco Cavallieri, Carla Budriesi, Carla Budriesi, Annalisa Gessani, Annalisa Gessani, Sara Contardi, Sara Contardi, Valentina Fioravanti, Elisa Menozzi, Elisa Menozzi, Elisa Menozzi, Serge Pinto, Elena Moro, Franco Valzania, Francesca Antonelli, Francesca Antonelli   +16 more
doaj   +1 more source

What contributes to depression in Parkinson's disease? [PDF]

, 2001
Background: Depression is a common problem in patients with Parkinson's disease, but its mechanism is poorly understood. It is thought that neurochemical changes contribute to its occurrence, but it is unclear why some patients develop depression and ...
Jahanshahi, M., Quinn, N.P., Schrag, A.
core   +1 more source

The Acute Brain Response to Levodopa Heralds Dyskinesias in Parkinson Disease [PDF]

, 2014
OBJECTIVE: In Parkinson disease (PD), long‐term treatment with the dopamine precursor levodopa gradually induces involuntary “dyskinesia” movements. The neural mechanisms underlying the emergence of levodopa‐induced dyskinesias in vivo are still poorly ...
Christensen, Mark S., Haagensen, Brian N., Herz, Damian M., Løkkegaard, Annemette, Madsen, Kristoffer Hougaard, Rowe, James B., Siebner, Hartwig R.   +6 more
core   +1 more source

7-Nitroindazole reduces L-DOPA-induced dyskinesias in non-human Parkinsonian primate

Open Biology, 2023
Nitric oxide (NO) plays a pivotal role in integrating dopamine transmission in the basal ganglia and has been implicated in the pathogenesis of Parkinson disease (PD).
M. T. Herrero, J. E. Yuste, L. Cuenca-Bermejo, P. Almela, L. Arenas-Betancur, V. De Pablos, A. Gonzalez-Cuello, E. Del Bel, J. Navarro-Zaragoza, E. Fernández-Villalba   +9 more
doaj   +1 more source

Implanted Reuptake-deficient or Wild-type Dopaminergic Neurons Improve ON L-dopa Dyskinesias Without OFF-dyskinesias in a Rat Model of Parkinson's Disease [PDF]

, 2012
OFF-L-dopa dyskinesias have been a surprising side-effect of intrastriatal foetal ventral mesencephalic transplantation in patients with Parkinson's disease.
Caron, M. G., Gainetdinov, R. R., Hallett, Penelope Jane, Isacson, Ole Stefan, Patterson, M., Reske-Nielsen, C., Sotnikova, T. D., Vinuela, Angel   +7 more
core   +1 more source

Clinical Aspects and Management of Levodopa-Induced Dyskinesia

Parkinson's Disease, 2012
In Parkinson's disease, one of the most troublesome dilemmas is the treatment of levodopa-induced dyskinesia. After a few years, chronic treatment with levodopa is associated with the development of dyskinesias.
Nicola Tambasco, Simone Simoni, Erica Marsili, Elisa Sacchini, Donatella Murasecco, Gabriela Cardaioli, Aroldo Rossi, Paolo Calabresi   +7 more
doaj   +1 more source

Levodopa Dose-Limiting Dyskinesias in Treatment of Segawa Disease

Pediatric Neurology Briefs, 2012
Researchers at the University of Cordoba, and other centers in Spain, Germany and New York report an atypical phenotype of persistent, low-dose levodopa treatment-limiting dyskinesias in 2 members of a family (female child aged 13 years and mother) with ...
J Gordon Millichap
doaj   +1 more source